TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1722835

Group type: EXPERIMENTAL
Intervention: Biologically active helevin-based compositions (BAC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ointments with antibiotics and antiseptics on a fat base (Control)
Number of subjects: 28
Study: 6749828

Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 80
Study: 30633202

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) plus montelukast
Number of subjects: 72

Group type: COMPARATOR
Intervention: Montelukast alone
Number of subjects: 72
Study: 28609542

Group type: EXPERIMENTAL
Intervention: Single-use, laser-cut, slow-flow nipples
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard-flow nipples
Number of subjects: 13
Study: 26559412

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) in aMCI group (MD group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) in control group (CD group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline in aMCI group (MN group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline in control group (CN group)
Number of subjects: 200
Study: 25119602

Group type: EXPERIMENTAL
Intervention: Chronic atrophic gastritis cases
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Chronic superficial gastritis cases
Number of subjects: 301

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 301

Group type: COMPARATOR
Intervention: Overall comparison of gastritis cases vs healthy controls
Number of subjects: 301
Study: 23084481

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (60 Gy of conventional irradiation to the surgical bed for 6 weeks)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 1005
Study: 18554182

Group type: EXPERIMENTAL
Intervention: Single 90-min bout of strenuous isokinetic resistance exercise (3 sets x 10 repetitions, 12 exercises at 80% of maximum peak torque production, 2-min rest between exercises)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single 90-min bout of strenuous isokinetic resistance exercise
Number of subjects: 8
Study: 17157339

Group type: EXPERIMENTAL
Intervention: 10-steroid profile measured by tandem mass spectrometry during high dose cortrosyn stimulation test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-steroid profile
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single aldosterone value
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 11-deoxycortisol, dehydroepiandrosterone, and two-steroid profile
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulated levels of aldosterone, 11-deoxycortisol, dehydroepiandrosterone, and two- or three-steroid profile
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroid profile measuring cortisol, aldosterone, 11-deoxycortisol, and dehydroepiandrosterone
Number of subjects: 0
Study: 15750416

Group type: EXPERIMENTAL
Intervention: Low-dose inductive chemotherapy, surgery, and then radiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (surgery and radiotherapy only)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cytostatic treatment with adequate tissue regression
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Changes in expressions of laminin and syndecan-1 in response to cytostatic treatment
Number of subjects: 60
Study: 11772810

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clonidine 3 microg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 90
Study: 10617008

Group type: EXPERIMENTAL
Intervention: Intraoperative administration of 3000 IU of antithrombin III (AT III) concentrates plus heparin (Group A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Heparin only (Group B)
Number of subjects: 22
Study: 7671358

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 2303172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 176
Study: 6250928

Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon
Number of subjects: 44

Group type: COMPARATOR
Intervention: Antacid gel (magnesium and aluminium hydroxide)
Number of subjects: 44
Study: 30985210

Group type: EXPERIMENTAL
Intervention: ScvO2 < 70%
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Lactate levels
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Acidemia
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Alactic base excess
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Fluid balance
Number of subjects: 1741
Study: 27820728

Group type: EXPERIMENTAL
Intervention: 100-times stretching treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: 50-times stretching treatment
Number of subjects: 50
Study: 24575727

Group type: EXPERIMENTAL
Intervention: Exercise-labels
Number of subjects: 300

Group type: COMPARATOR
Intervention: No-labels
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Kcal-labels
Number of subjects: 300
Study: 23928892

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 253

Group type: COMPARATOR
Intervention: White-light endoscopy (WLE)
Number of subjects: 253
Study: 22403970

Group type: EXPERIMENTAL
Intervention: Prophylactic inhalation of isopropyl alcohol (IPA) vapors with IV ondansetron
Number of subjects: 76

Group type: COMPARATOR
Intervention: IV ondansetron alone
Number of subjects: 76
Study: 19017751

Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3548
Study: 17524288

Group type: EXPERIMENTAL
Intervention: OraSure oral fluid testing
Number of subjects: 354
Study: 15455744

Group type: EXPERIMENTAL
Intervention: Digital subtraction radiography
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional radiographic interpretation
Number of subjects: 18
Study: 11266197

Group type: EXPERIMENTAL
Intervention: Middleoxic (PO2=500+/‐50 mmHg) reperfusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: More physiologic (PO2=200‐250 mmHg) cardiopulmonary bypass
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hyperoxic (PO2=450‐550 mmHg) cardiopulmonary bypass
Number of subjects: 21
Study: 9791322

Group type: EXPERIMENTAL
Intervention: Mood clarity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depressive symptoms and pessimism
Number of subjects: 0
Study: 7987882

Group type: EXPERIMENTAL
Intervention: 5 mg/day simvastatin
Number of subjects: 281

Group type: COMPARATOR
Intervention: 10 mg/day pravastatin
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 10 mg/day simvastatin
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: simvastatin
Number of subjects: 281

Group type: COMPARATOR
Intervention: pravastatin
Number of subjects: 281
Study: 2547465

Group type: EXPERIMENTAL
Intervention: Intravenous doses of lisinopril
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral doses of lisinopril (10 daily doses, q24h)
Number of subjects: 3
Study: 5302328

Group type: EXPERIMENTAL
Intervention: Whole-cell cholera vaccine, 0.5 ml dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purified Ogawa antigen, 100 mug dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-cell cholera vaccine, 0.4 ml dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-cell cholera vaccine
Number of subjects: 0
Study: 31877361

Group type: EXPERIMENTAL
Intervention: 6-session asthma self-management intervention
Number of subjects: 189
Study: 31209698

Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Strips (BRNS)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 270
Study: 29151315

Group type: EXPERIMENTAL
Intervention: 200 mg/day oral iron for 3 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral placebo for 3 months
Number of subjects: 90
Study: 26496720

Group type: EXPERIMENTAL
Intervention: Low Level Laser (LLL) applied at the point of greatest pain, 10 patients, 12 sessions, 3 times per week.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low Level Laser (LLL) applied at pre-established points in the affected muscles, 10 patients, 12 sessions, 3 times per week.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group, 10 patients, 12 sessions, 3 times per week.
Number of subjects: 30
Study: 23680766

Group type: EXPERIMENTAL
Intervention: agalsidase alfa (0.2 mg/kg every other week for 12 months)
Number of subjects: 73

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: agalsidase alfa
Number of subjects: 73
Study: 22012809

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tranexamic acid (loading dose of 500 mg before surgery followed by continuous infusion of 250 mg/h during surgery)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tranexamic acid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous infusion of tranexamic acid and placebo
Number of subjects: 200
Study: 19691851

Group type: EXPERIMENTAL
Intervention: Artesunate and amodiaquine fixed dose combination (FDC)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Artesunate and amodiaquine given in separate tablets
Number of subjects: 140
Study: 17005447

Group type: EXPERIMENTAL
Intervention: Pulsed EMF emitted by a mobile phone for 30 minutes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 16
Study: 15747942

Group type: EXPERIMENTAL
Intervention: Community-based nurses visiting patients in the home as part of shared care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous phase without monitoring facilities at the patient's home.
Number of subjects: 0
Study: 11028740

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20
Study: 9118699

Group type: EXPERIMENTAL
Intervention: L‐5‐hydroxytryptophan (L‐5‐HTP), 0.4 mg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: nCPAP-treated OSA patients
Number of subjects: 11
Study: 8100625

Group type: EXPERIMENTAL
Intervention: 0.5% brimonidine before and after ALT
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Brimonidine before but vehicle after ALT
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Vehicle before but brimonidine after ALT
Number of subjects: 232

Group type: COMPARATOR
Intervention: Vehicle at both times
Number of subjects: 232
Study: 3558443

Group type: EXPERIMENTAL
Intervention: Siliconized tetrafluorethylene cannula
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heparinized tetrafluorethylene cannula
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluorethylenpropylene cannula
Number of subjects: 30
Study: 29996844

Group type: EXPERIMENTAL
Intervention: 3-day course of artemether-lumefantrine (AL)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 5-day course of artemether-lumefantrine (AL)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Both regimens (3-day and 5-day AL)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Parasite clearance profiles
Number of subjects: 154
Study: 28581398

Group type: EXPERIMENTAL
Intervention: Dose-escalated external beam (DE‐EBRT) boost
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Low-dose-rate prostate brachytherapy (LDR‐PB) boost
Number of subjects: 357
Study: 26621252

Group type: EXPERIMENTAL
Intervention: Antidepressant medication at baseline
Number of subjects: 4393

Group type: EXPERIMENTAL
Intervention: Antidepressant medication at follow up
Number of subjects: 4393

Group type: EXPERIMENTAL
Intervention: CESD-10 scores at follow-up
Number of subjects: 4393

Group type: EXPERIMENTAL
Intervention: CESD-10 scores of ten or more at baseline
Number of subjects: 4393
Study: 24089493

Group type: EXPERIMENTAL
Intervention: tDCS(anodal) over left IFG
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: tDCS(anodal) over left IPC
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 36
Study: 21440468

Group type: EXPERIMENTAL
Intervention: Ski cap only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ski helmet only
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ski cap and ski goggles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ski helmet and ski goggles
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study: 19146601

Group type: EXPERIMENTAL
Intervention: Capryloyl salicylic acid (LHA) peel (5-10%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glycolic acid (GA) peel (20-50%)
Number of subjects: 50
Study: 16464637

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (N=8)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nicorandil (N=12)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 14500473

Group type: EXPERIMENTAL
Intervention: One dose of MCC-TT vaccine
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Two doses of MCC-TT vaccine
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Three doses of MCC-TT vaccine
Number of subjects: 586
Study: 10710869

Group type: EXPERIMENTAL
Intervention: Computed X-ray densitometry (CXD) measurement of metacarpal bone mineral density (mBMD) and metacarpal index (MCI)
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Normal young population
Number of subjects: 1182
Study: 8992904

Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (younger groups 18-50 and 51-64)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: All relaxants (Atracurium, Rocuronium, Vecuronium)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 108
Study: 1394812

Group type: COMPARATOR
Intervention: Intravesical thio-TEPA at 30 mg/30 ml physiological saline, instilled 32 times over 2 years (group T)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Oral UFT given at 1296 mg/day for 2 years (group U)
Number of subjects: 153

Group type: COMPARATOR
Intervention: No prophylactic treatment (group C)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Intravesical thio-TEPA (group T)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Oral UFT (group U)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Group C
Number of subjects: 153

Group type: COMPARATOR
Intervention: Group U
Number of subjects: 153

Group type: COMPARATOR
Intervention: Group T
Number of subjects: 153
Study: 3900847

Group type: EXPERIMENTAL
Intervention: Tocopherol treatment (early parenteral tocopherol given from day one)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo treatment (control group)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Tocopherol treatment
Number of subjects: 287
Study: 30530284

Group type: EXPERIMENTAL
Intervention: Highest quartile of hemoglobin
Number of subjects: 3881

Group type: COMPARATOR
Intervention: Lowest quartile of hemoglobin
Number of subjects: 3881
Study: 30256746

Group type: EXPERIMENTAL
Intervention: New skin protectant
Number of subjects: 21

Group type: COMPARATOR
Intervention: Other 3 products
Number of subjects: 21
Study: 26891156

Group type: EXPERIMENTAL
Intervention: Dynamic simulator
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cadaver
Number of subjects: 54
Study: 24142966

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Hypofraction stereotactic radiotherapy (HSRT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional fraction stereotactic radiotherapy (CSRT)
Number of subjects: 139
Study: 22133776

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/day
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg/day
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Thalidomide 400 mg/day
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Thalidomide (all doses)
Number of subjects: 499
Study: 19840063

Group type: EXPERIMENTAL
Intervention: Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fucoxanthin (> 2.4 mg)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin)
Number of subjects: 151
Study: 17555170

Group type: EXPERIMENTAL
Intervention: Interdental wooden wedge (Hawe‐Neos)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Separation ring (Composi‐Tight Gold)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Wooden wedge combined with separation ring (Composi‐Tight Gold)
Number of subjects: 27
Study: 15361517

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 3

Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 3

Group type: COMPARATOR
Intervention: Controlled hypertensive subjects
Number of subjects: 3

Group type: COMPARATOR
Intervention: Uncontrolled hypertensive subjects
Number of subjects: 3
Study: 16982237

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group (no suppository treatment)
Number of subjects: 217
Study: 10371772

Group type: EXPERIMENTAL
Intervention: Epidemiological study of Alzheimer's disease
Number of subjects: 4134
Study: 8878773

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunts
Number of subjects: 25

Group type: COMPARATOR
Intervention: Paracentesis
Number of subjects: 25
Study: 1999775

Group type: EXPERIMENTAL
Intervention: PRP-tetanus toxoid (PRP-T) in Pennsylvania
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: PRP-outer membrane protein (OMP)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: PRP-D in Dallas
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Hib oligosaccharide-CRM197 (HbOC)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Children with prevaccination antibody > 0.15 microgram/ml
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Children with prevaccination antibody ≤ 0.15 microgram/ml
Number of subjects: 313
Study: 6141317

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Beta-blocker group (Atenolol)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Diuretic group (Hydrochlorothiazide)
Number of subjects: 34
Study: 31568142

Group type: EXPERIMENTAL
Intervention: Cognitive measures including Intelligence Quotient tests, Color Trails Tests, and Beery-Buktenica Developmental Test of Visual-Motor Integration conducted semiannually over 3-6 years.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lowest scoring trajectory group characteristics
Number of subjects: 0
Study: 29431146

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus hyperbaric oxygen therapy (HBOT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 60
Study: 26353751

Group type: EXPERIMENTAL
Intervention: Fixed Tc‐99m tetrofosmin tracer dose
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Body-weight-dependent protocol
Number of subjects: 148
Study: 24612764

Group type: EXPERIMENTAL
Intervention: Automatic adjustment (AA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fixed termination criterion
Number of subjects: 16
Study: 22864525

Group type: EXPERIMENTAL
Intervention: Intratympanic gadolinium injection (gadolinium‐diethylene‐triamine pentaacetic acid diluted eightfold with saline)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intravenous gadolinium injection (double dose of gadoteridol (0.5 mmol/ml); 0.2 mmol/kg body weight)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intratympanic gadolinium injection
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intravenous gadolinium injection
Number of subjects: 39
Study: 21330796

Group type: EXPERIMENTAL
Intervention: Hybrid simulation (HYB) with patient-actor
Number of subjects: 24

Group type: COMPARATOR
Intervention: Small-group tutorial (SGT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (HYB and SGT)
Number of subjects: 24
Study: 17475531

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with bolus optimization and sulfonylurea at bedtime
Number of subjects: 59

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII) with basal rate optimization and sulfonylurea before meals
Number of subjects: 59
Study: 16091670

Group type: EXPERIMENTAL
Intervention: Physical exercise (moderate intensity dynamic exercise, 30-40 min, 4-5 sessions per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (addition to pharmacological therapy)
Number of subjects: 0
Study: 12041718

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350 (10 g/m2/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Lactulose (1.3 g/kg/d divided twice daily up to 20 g)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350
Number of subjects: 37

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 37
Study: 10066991

Group type: EXPERIMENTAL
Intervention: Negative-symptom group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive-symptom group
Number of subjects: 0
Study: 7478050

Group type: EXPERIMENTAL
Intervention: COF (modified Fick method using mixed venous O2 content)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: COFra (modified Fick method using central venous O2 content)
Number of subjects: 10

Group type: COMPARATOR
Intervention: COTD (thermodilution technique, gold standard)
Number of subjects: 10
Study: 31088342

Group type: EXPERIMENTAL
Intervention: Real dual-tDCS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham dual-tDCS
Number of subjects: 21